Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate

References

• Finucane MM Stevens GA Cowan MJ Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index) National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants Lancet 2011 377 9765 557 567 21295846
   PubMed Web of Science ®Google Scholar
• Vasan RS Pencina MJ Cobain M Freiberg MS D’Agostino RB Estimated risks for developing obesity in the Framingham Heart Study Ann Intern Med 2005 143 7 473 480 16204159
   PubMed Web of Science ®Google Scholar
• Kelly T Yang W Chen CS Reynolds K He J Global burden of obesity in 2005 and projections to 2030 Int J Obes (Lond) 2008 32 9 1431 1437 18607383
   PubMed Web of Science ®Google Scholar
• Bleich SN Bennett WL Gudzune KA Cooper LA Impact of physician BMI on obesity care and beliefs Obesity (Silver Spring) 2012 20 5 999 1005 22262162
   PubMed Web of Science ®Google Scholar
• Adams KF Schatzkin A Harris TB Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old N Engl J Med 2006 355 8 763 778 16926275
   PubMed Web of Science ®Google Scholar
• Whitlock G Lewington S Sherliker P Prospective Studies Collaboration Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies Lancet 2009 373 9669 1083 1096 19299006
   PubMed Web of Science ®Google Scholar
• Goldstein DJ Beneficial health effects of modest weight loss Int J Obes Relat Metab Disord 1992 16 6 397 415 1322866
   PubMed Web of Science ®Google Scholar
• Poirier P Giles TD Bray GA American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism Circulation 2006 113 6 898 918 16380542
   PubMed Web of Science ®Google Scholar
• James WP Caterson ID Coutinho W SCOUT Investigators Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects N Engl J Med 2010 363 10 905 917 20818901
   PubMed Web of Science ®Google Scholar
• Mark EJ Patalas ED Chang HT Evans RJ Kessler SC Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine N Engl J Med 1997 337 9 602 606 9271482
   PubMed Web of Science ®Google Scholar
• Connolly HM Crary JL McGoon MD Valvular heart disease associated with fenfluramine-phentermine N Engl J Med 1997 337 9 581 588 9271479
   PubMed Web of Science ®Google Scholar
• Yanovski SZ Yanovski JA Long-term drug treatment for obesity: a systematic and clinical review JAMAEpub 11 14 2013
   Google Scholar
• Bray GA Ryan DH Medical therapy for the patient with obesity Circulation 2012 125 13 1695 1703 22474312
   PubMed Web of Science ®Google Scholar
• Lorello C Goldfield GS Doucet E Methylphenidate hydrochloride increases energy expenditure in healthy adults Obesity (Silver Spring) 2008 16 2 470 472 18239661
   PubMed Web of Science ®Google Scholar
• Pasquali R Casimirri F Melchionda N Effects of chronic administration of ephidrine during very-low-calorie diets on energy expenditure, protein metabolism and hormone levels in obese subjects Clin Sci (Lond) 1992 82 1 85 92 1310922
   PubMed Web of Science ®Google Scholar
• Derosa G Maffioli P Anti-obesity drugs: a review about their effects and their safety Expert Opin Drug Saf 2012 11 3 459 471 22439841
   PubMed Web of Science ®Google Scholar
• Li Z Maglione M Tu W Meta-analysis: pharmacologic treatment of obesity Ann Intern Med 2005 142 7 532 546 15809465
   PubMed Web of Science ®Google Scholar
• Douglas A Douglas JG Robertson CE Munro JF Plasma phentermine levels, weight loss and side-effects Int J Obes 1983 7 6 591 595 6654575
   PubMed Web of Science ®Google Scholar
• Hendricks EJ Greenway FL A study of abrupt phentermine cessation in patients in a weight management program Am J Ther 2011 18 4 292 299 20592662
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration Clinical Briefing Document, Endocrine and Metabolic Drugs Advisory Committee Meeting, February 22, 2012 New Drug Application 22580: VI-052 Qnexa (phentermine/topiramate) Silver Spring, MD Food and Drug Administration 2012 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM292315.pdf Accessed July 3, 2013
   Google Scholar
• Braga MF Aroniadou-Anderjaska V Li H Rogawski MA Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons J Pharmacol Exp Ther 2009 330 2 558 566 19417176
   PubMed Web of Science ®Google Scholar
• Verrotti A Scaparrotta A Agostinelli S Di Pillo S Chiarelli F Grosso S Topiramate-induced weight loss: a review Epilepsy Res 2011 95 3 189 199 21684121
   PubMed Web of Science ®Google Scholar
• Picard F Deshaies Y Lalonde J Samson P Richard D Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats Obes Res 2000 8 9 656 663 11225714
   PubMedGoogle Scholar
• Tonstad S Tykarski A Weissgarten J Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension Am J Cardiol 2005 96 2 243 251 16018851
   PubMed Web of Science ®Google Scholar
• Shank RP Gardocki JF Streeter AJ Maryanoff BE An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action Epilepsia 2000 41 Suppl 1 S3 S9 10768292
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E Axelsen M Johanson EH Stagge A Smith U Predictors of weight loss in adults with topiramate-treated epilepsy Obes Res 2003 11 4 556 562 12690085
   PubMedGoogle Scholar
• Gadde KM Allison DB Ryan DH Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial Lancet 2011 377 9774 1341 1352 21481449
   PubMed Web of Science ®Google Scholar
• Brandes JL Saper JR Diamond M MIGR-002 Study Group Topiramate for migraine prevention: a randomized controlled trial JAMA 2004 291 8 965 973 14982912
   PubMed Web of Science ®Google Scholar
• Henry RR Chilton R Garvey WT New options for the treatment of obesity and type 2 diabetes mellitus (narrative review) J Diabetes Complications 2013 27 5 508 518 23726071
   PubMed Web of Science ®Google Scholar
• Padwal R Li SK Lau DC Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials Int J Obes Relat Metab Disord 2003 27 12 1437 1446 12975638
   PubMed Web of Science ®Google Scholar
• Torgerson JS Hauptman J Boldrin MN Sjöström L XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients Diabetes Care 2004 27 1 155 161 14693982
   PubMed Web of Science ®Google Scholar
• Rössner S Sjöström L Noack R Meinders AE Noseda G Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group Obes Res 2000 8 1 49 61 10678259
   PubMedGoogle Scholar
• Bays HE Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for ‘sick fat’ and metabolic disease Expert Rev Cardiovasc Ther 2009 7 11 1429 1445 19900026
   PubMedGoogle Scholar
• Smith SR Weissman NJ Anderson CM Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group Multicenter, placebo-controlled trial of lorcaserin for weight management N Engl J Med 2010 363 3 245 256 20647200
   PubMed Web of Science ®Google Scholar
• Fidler MC Sanchez M Raether B BLOSSOM Clinical Trial Group A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial J Clin Endocrinol Metab 2011 96 10 3067 3077 21795446
   PubMed Web of Science ®Google Scholar
• O’Neil PM Smith SR Weissman NJ Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study Obesity (Silver Spring) 2012 20 7 1426 1436 22421927
   PubMed Web of Science ®Google Scholar
• Wyatt HR Update on treatment strategies for obesity J Clin Endocrinol Metab 2013 98 4 1299 1306 23443815
   PubMed Web of Science ®Google Scholar
• Ryan D Peterson C Troupin B Weight loss at 6 months with VI-0521 (PHEN/TPM combination) treatment Obes Facts 2010 3146
   Google Scholar
• Robert M Clinical Briefing Document Endocrinologic and Metabolic Drugs Advisory Committee Meeting for phentermine/topiramate (Qnexa)Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingsMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM218824.pdf(2010) Accessed August 9, 2013
   Google Scholar
• Bays H Phentermine, topiramate and their combination for the treatment of adiposopathy (‘sick fat’) and metabolic disease Expert Rev Cardiovasc Ther 2010 8 12 1777 1801 20707765
   PubMedGoogle Scholar
• Allison DB Gadde KM Garvey WT Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP) Obesity (Silver Spring) 2012 20 2 330 342 22051941
   PubMed Web of Science ®Google Scholar
• Garvey WT Ryan DH Look M Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study Am J Clin Nutr 2012 95 2 297 308 22158731
   PubMed Web of Science ®Google Scholar
• Winslow DH Bowden CH DiDonato KP McCullough PA A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults Sleep 2012 35 11 1529 1539 23115402
   PubMed Web of Science ®Google Scholar
• Margulis AV Mitchell AA Gilboa SM National birth defects prevention study. Use of topiramate in pregnancy and risk of oral clefts Am J Obstet Gynecol 2012 207 405e1 e7 22917484
   PubMed Web of Science ®Google Scholar
• Hunt S Russell A Smithson WH UK Epilepsy and Pregnancy Register Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register Neurology 2008 71 4 272 276 18645165
   PubMed Web of Science ®Google Scholar
• Mirza N Marson AG Pirmohamed M Effect of topiramate on acid-base balance: extent, mechanism and effects Br J Clin Pharmacol 2009 68 5 655 661 19916989
   PubMed Web of Science ®Google Scholar
• Epstein DL Grant WM Carbonic anhydrase inhibitor side effects. Serum chemical analysis Arch Ophthalmol 1977 95 8 1378 1382 889513
   PubMedGoogle Scholar
• Zhou YH Effect of anti-obesity drug on cardiovascular risk factors: A systematic review and meta-analysis of randomised controlled trials PLoS One 2012 7 6 e39062 22745703
   PubMed Web of Science ®Google Scholar
• Rueda-Clausen CF Padwal RS Sharma AM New pharmacological approaches for obesity management Nat Rev Endocrinol 2013 9 467 478 23752772
   PubMed Web of Science ®Google Scholar